Form 4: Roivant Director Receives Equity Awards, Sells Shares for Tax

Roivant Sciences Director Melissa Epperly was granted new equity awards and sold shares to cover tax obligations related to prior vesting.

Summary

• Melissa B. Epperly, a Director at Roivant Sciences Ltd. (ROIV), reported transactions on September 10, 2025.
• Epperly acquired 14,524 Common Shares in the form of Restricted Stock Units (RSUs) at a price of $0, as an annual award under the company's 2021 Equity Incentive Plan and Non-Employee Director Compensation Policy.
• These RSUs are scheduled to vest 100% on September 10, 2026, contingent on continuous service.
• Epperly disposed of 1,661 Common Shares at $13.77 per share through a 'net settlement' to satisfy tax withholding obligations related to the vesting and settlement of previously granted Common Shares.
• Epperly also acquired 33,726 stock options to purchase Common Shares at an exercise price of $13.77, as an annual award under the same compensation plans.
• These stock options are scheduled to vest and become exercisable 100% on September 10, 2026, subject to continuous service, and expire on September 9, 2035.
• Following these transactions, Epperly beneficially owns 55,848 direct Common Shares and 33,726 direct stock options.

Sentiment

Score: 6

Explanation: The filing indicates routine compensation events for a director, including new equity awards which are generally positive for aligning interests, and a standard tax-related share disposition. No significant positive or negative surprises.

Positives

• Director Melissa Epperly received an annual award of 14,524 Restricted Stock Units (RSUs), aligning her interests with long-term company performance.
• An annual award of 33,726 stock options was granted to Director Epperly, providing further incentive tied to share price appreciation.

Negatives

• 1,661 Common Shares were disposed of to cover tax withholding obligations, representing a reduction in direct share ownership, albeit for a routine purpose.

Future Outlook

The newly granted Restricted Stock Units and stock options are scheduled to vest and become exercisable on September 10, 2026, subject to the director's continuous service.

Stakeholder Impact

• Shareholders: The issuance of new equity awards may result in minor dilution over time, but also aligns director incentives with shareholder value creation. The tax-related sale is a routine event with minimal impact.
• Employees: The equity incentive plan provides a framework for compensation, potentially impacting employee retention and motivation if similar plans are offered.

Next Steps

• The 14,524 RSUs and 33,726 stock options are expected to vest and become exercisable on September 10, 2026, provided the reporting person maintains continuous service.

Key Dates

Recommendation

This Form 4 details routine insider transactions related to director compensation, including annual equity awards and a tax-related share disposition. Such transactions are generally expected and do not typically signal a material change in the company's fundamentals or outlook, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Roivant Sciences, ROIV, Form 4, Insider Trading, Equity Awards, Restricted Stock Units, Stock Options, Director Compensation, Executive Compensation, Share Disposition, Tax Withholding